RxDoctor Payments DataLook up a doctor →

Stella Ilyayeva, MD

Endocrinology, Diabetes & Metabolism · Rego Park, NYNPI 1619082625

Payments from drug & device makers

$219,096in general payments, 2019–2025

Across 1,523 payments — averaging $143.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$117K
  • Boehringer Ingelheim$28K
  • Mannkind Corporation$22K
  • AstraZeneca$19K
  • Merck$8K
  • Lilly USA, LLC$5K
  • plus $20K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)272$116,713
Boehringer Ingelheim70$27,802
Mannkind Corporation222$22,259
AstraZeneca65$19,221
Merck37$8,103
Lilly USA, LLC51$5,209
Novo Nordisk114$2,588
AbbVie(2 entities)80$1,539
Medtronic(2 entities)43$1,433
Sanofi-aventis U.S. LLC59$1,307
Corcept Therapeutics38$1,287
Abbott41$931
Xeris Pharmaceuticals, Inc.44$871
Dexcom, Inc.26$818
Amphastar Pharmaceuticals, Inc.47$752
Intuity Medical Inc34$719
Bayer29$704
Cequr Corporation4$541
Johnson & Johnson21$533
Insulet Corporation20$524
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC26$474
Intra-sana Laboratories14$379
Amarin Pharma, Inc.13$356
Esperion Therapeutics, Inc.8$277
Nevro Corp.5$243
Tandem Diabetes Care, Inc.9$239
OPKO Pharmaceuticals, LLC10$220
Shire North American Group Inc5$218
Amneal Pharmaceuticals LLC8$199
Chiesi USA, Inc.7$197
Endo Pharmaceuticals Inc.9$192
Ascendis Pharma Endocrinology Inc3$158
Amryt Pharma Holdings Ltd3$155
Novartis7$149
Regeneron Healthcare Solutions, Inc.5$144
Astellas Pharma US Inc6$134
Phathom Pharmaceuticals, Inc.6$130
Axsome Therapeutics, Inc.2$113
Ironwood Pharmaceuticals, Inc5$98
Avvisto Therapeutics, LLC5$92
Ipsen Biopharmaceuticals, Inc4$77
Ascensia Diabetes Care US Inc.1$72
GSK3$62
Vistapharm, Inc.3$58
Eisai Inc.2$48
Exact Sciences2$48
Lifescan, Inc.2$45
Nestle Healthcare Nutrition Inc.2$42
BETA Bionics, Inc.2$42
Alfasigma USA, Inc.2$41
Sanofi Pasteur Inc.2$36
Rhythm Pharmaceuticals, Inc.2$36
Renalytix AI, Inc.2$36
Kowa Pharmaceuticals America, Inc.2$34
Dynavax Technologies Corporation1$30
Aimmune Therapeutics, Inc.1$28
Azurity Pharmaceuticals, Inc.1$25
Takeda Pharmaceuticals U.S.A., Inc.1$25
BD1$25
Sumitomo Pharma America, Inc.1$24

How this compares

$219,096 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024
$870,930
Medicare patients
1,075
Services billed
25,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Rego Park

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →